What is the 13F Pro Quality Score for KRYS?

13F Pro ranks Krystal Biotech, Inc. (KRYS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KRYS's current score at https://13fpro.ai/company/KRYS (free sign-up required for the full ranking).

Which hedge funds own the most KRYS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of KRYS include FMR, BlackRock,, Avoro Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/KRYS as soon as new 13F filings post.

Where does 13F Pro source KRYS data?

All Krystal Biotech, Inc. fundamentals and ownership data come directly from SEC EDGAR. Krystal Biotech, Inc. files with the SEC under CIK 1711279. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KRYS in?

Krystal Biotech, Inc. (KRYS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives KRYS's revenue?

Per Krystal Biotech, Inc.'s latest 10-Q filed with the SEC on 2026-08-03, the biggest revenue drivers are: United States ($91.6M, vs $96.0M prior-year quarter); Europe ($19.3M); Japan ($8.3M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/KRYS.

What are KRYS's largest expenses?

Krystal Biotech, Inc.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($39.9M, +14% YoY); Research and development ($14.5M, +1% YoY); Cost of goods sold ($6.4M, -10% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is KRYS research updated on 13F Pro?

KRYS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Krystal Biotech, Inc.(KRYS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1711279 KRYS stock profile & AI dashboard →

13F Pro Quality Score

79.2/100

Rank #47 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

96.5/100

Profitability

98.4/100

Balance Sheet

95.3/100

Earnings Quality

63.7/100

Free Cash Flow

97.0/100

Institutional Flow

84.5/100

Revenue Scale

34.9/100

Dilution Risk

12.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why KRYS Scores 79/100

exact factor attribution · 2026-09-11

KRYS's composite is driven by revenue growth and profitability, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.3 pts

97th pct

Profitability

+7.3 pts

98th pct

Free cash flow

+7.0 pts

97th pct

Capital efficiency

+4.5 pts

95th pct

Earnings growth

+2.2 pts

93th pct

Institutional flow

+1.7 pts

85th pct

Earnings quality

+1.4 pts

64th pct

Shareholder dilution

-1.9 pts

13th pct

Scale

-2.3 pts

35th pct

Latest change (2026-08-05): 76 → 78 · ↑ Earnings growth 30→75

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

KRYS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Krystal Biotech, Inc. (KRYS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRYS at 79.2/100 on a 32-signal composite quality model, placing it at rank #47 of 2,961 stocks — the top 5% of the AI-ranked universe. KRYS scores in the top quartile across profitability (98.4), free cash flow (97.0), revenue growth (96.5). Areas of concern include revenue scale (34.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Krystal Biotech, Inc. reports quarterly revenue of $119.2M, net income of $54.8M, an operating margin of 49.0%. Top institutional holders of KRYS by reported 13-F value include FMR, BlackRock, Avoro Capital Advisors, based on the most recent SEC filings. KRYS trades on the Nasdaq exchange and files with the SEC under CIK 1711279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRYS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Krystal Biotech, Inc. directly from SEC EDGAR. Krystal Biotech, Inc.'s 13F Pro composite quality score has ranged between 30 and 80 since 2024, currently 79.2 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Krystal Biotech, Inc.

Quirks, history, and lore behind KRYS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the hundreds of millions of dollars — remarkable for a company that only recently transitioned from clinical-stage to commercial in a matter of a few years.
3
The History
Founded in 2016, it moved unusually fast from startup to approved product, built around a proprietary gene therapy delivery platform using modified herpes simplex virus vectors.
4
The Secret
Unlike most gene therapy players chasing one-and-done injections, this company's approach delivers treatment topically — straight to the skin — which is a genuinely weird flex in the gene therapy world.
5
The Lore
Its lead product targets dystrophic epidermolysis bullosa — a devastating rare skin disease nicknamed "butterfly skin" — giving patients something they'd never had before: an actual approved treatment.
6
The Giveaway
Its FDA-approved gel Vyjuvek is the first-ever redosable gene therapy, and the company's name sounds like it belongs in a fantasy novel but is spelled with a K and a Y.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving KRYS's Business? Latest 10-Q Breakdown

✓ 33/33 datapoints verified

AI-extracted from Krystal Biotech, Inc.'s 10-Q filed 2026-08-03 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

VYJUVEK product revenue rose 24% YoY to $119.2M as Europe ($19.3M) and Japan ($8.3M) launches offset a decline in U.S. sales, lifting net income 43% to $54.8M.

Biggest Revenue Drivers

United States$91.6Mvs $96.0M prior-year quarter

Filing cites a reduction in United States VYJUVEK sales

Europe$19.3M

New market; VYJUVEK launched in Germany August 2025 and France October 2025, with pricing negotiations ongoing

Biggest Revenue Drivers

Total revenue: $119.2M+24% YoY

United States$91.6Mvs $96.0M prior-year quarter

Filing cites a reduction in United States VYJUVEK sales

Europe$19.3M

New market; VYJUVEK launched in Germany August 2025 and France October 2025, with pricing negotiations ongoing

Japan$8.3M

New market; launched October 2025 after pricing negotiations were completed prior to launch

Largest Expense Items

Selling, general and administrative$39.9M+14% YoY

$2.5M higher payroll including stock-based compensation, $1.4M other G&A, $1.0M selling expenses

Research and development$14.5M+1% YoY

$0.8M higher clinical development for KB407, KB707, KB801, KB803, offset by lower B-VEC and KB304 spend

Cost of goods sold$6.4M-10% YoY

Manufacturing process optimizations lowered average cost per unit, partly offset by higher VYJUVEK sales

Margins: Gross margin was 95% for the quarter versus 93% a year earlier, as manufacturing process optimizations lowered average cost per unit. Income from operations rose 48% to $58.4M.

Watch Items from the Filing

Customer concentration: Customer A represents 54% and Customer B 18% of net accounts receivable at June 30, 2026 (66% and 14% at year-end 2025).
U.S. VYJUVEK revenue declined to $91.6M from $96.0M a year earlier, with growth now dependent on newer Europe and Japan markets.
DOJ subpoenas received in Q1 2025 regarding the sponsored genetic testing program for VYJUVEK; the Company cannot estimate any possible loss.
Pricing negotiations continue in Germany into at least 2H 2026 and France into 2027; Italy and Spain launches targeted for 2H 2026.
Accrued rebate reserves grew to $89.4M at June 30, 2026 from $61.9M, with $48.9M of provisions recorded against revenue in six months.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$119.2M

Net Income

Q2 2026

$54.8M

Free Cash Flow

Q2 2026

$71.2M

Operating Margin

Q2 2026

49.0%

ROIC

Q2 2026

17.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+33.9% YoY

$389.1MFY 2025

FY22 $0.00FY23 $50.7MFY24 $290.5MFY25 $389.1M

Net Income

+129.7% YoY

$204.8MFY 2025

FY22 $-140.0MFY23 $10.9MFY24 $89.2MFY25 $204.8M

Operating Income

+145.3% YoY

$161.3MFY 2025

FY22 $-145.2MFY23 $-109.6MFY24 $65.7MFY25 $161.3M

EPS (Diluted)

+128.0% YoY

$6.84FY 2025

FY22 $-5.49FY23 $0.39FY24 $3.00FY25 $6.84

Total Assets

+26.3% YoY

$1.33BFY 2025

FY22 $558.5MFY23 $818.4MFY24 $1.06BFY25 $1.33B

Op. Cash Flow

+62.7% YoY

$200.9MFY 2025

FY22 $-100.6MFY23 $-88.8MFY24 $123.4MFY25 $200.9M

Free Cash Flow

+58.5% YoY

$188.9MFY 2025

FY22 $-153.5MFY23 $-100.6MFY24 $119.2MFY25 $188.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$389.1M +33.9%	$290.5M +473.0%	$50.7M	$0.00	$0.00	—
Net Income	$204.8M +129.7%	$89.2M +715.6%	$10.9M +107.8%	$-140.0M -101.2%	$-69.6M -116.3%	$-32.2M
Operating Income	$161.3M +145.3%	$65.7M +160.0%	$-109.6M +24.5%	$-145.2M -112.7%	$-68.3M -106.9%	$-33.0M
EPS (Diluted)	$6.84 +128.0%	$3.00 +669.2%	$0.39 +107.1%	$-5.49 -75.4%	$-3.13 -83.0%	$-1.71
Total Assets	$1.33B +26.3%	$1.06B +29.0%	$818.4M +46.5%	$558.5M -10.8%	$626.3M +101.5%	$310.8M
Operating Cash Flow	$200.9M +62.7%	$123.4M +239.0%	$-88.8M +11.7%	$-100.6M -109.8%	$-47.9M -83.8%	$-26.1M
Free Cash Flow	$188.9M +58.5%	$119.2M +218.5%	$-100.6M +34.5%	$-153.5M -32.1%	$-116.3M -184.1%	$-40.9M

Get alerted when KRYS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Krystal Biotech, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KRYS

FMR LLC
$1.6B4,418,197 sh
BlackRock, Inc.
$1.6B4,181,432 sh
Avoro Capital Advisors LLC
$1.1B2,888,888 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$585.3M1,574,905 sh
STATE STREET CORP
$502.2M1,351,158 sh
VANGUARD CAPITAL MANAGEMENT LLC
$461.1M1,240,567 sh
Soleus Capital Management, L.P.
$349.1M939,254 sh
Capital World Investors
$289.1M777,843 sh
GEODE CAPITAL MANAGEMENT, LLC
$259.8M698,993 sh
PRICE T ROWE ASSOCIATES INC /MD/
$255.5M687,400 sh

Fund	Value	Shares
FMR LLC	$1.6B	4,418,197
BlackRock, Inc.	$1.6B	4,181,432
Avoro Capital Advisors LLC	$1.1B	2,888,888
VANGUARD PORTFOLIO MANAGEMENT LLC	$585.3M	1,574,905
STATE STREET CORP	$502.2M	1,351,158
VANGUARD CAPITAL MANAGEMENT LLC	$461.1M	1,240,567
Soleus Capital Management, L.P.	$349.1M	939,254
Capital World Investors	$289.1M	777,843
GEODE CAPITAL MANAGEMENT, LLC	$259.8M	698,993
PRICE T ROWE ASSOCIATES INC /MD/	$255.5M	687,400

Companies Similar to KRYS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

LGND

LIGAND PHARMACEUTICALS INC

AI score

Very similar · 26 shared holders

CONGRESS ASSET MANAGEMENT CO /MA Granite Investment Partners, LLC abrdn plc

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Similar quality profile · 24 shared holders

Hood River Capital Management LLC BRAIDWELL LP C WorldWide Group Holding A/S

KNSA

Kiniksa Pharmaceuticals International, plc

AI score

Similar quality profile · 19 shared holders

ORBIMED ADVISORS LLC Soleus Capital Management, L.P.BRAIDWELL LP

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 26 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC SEGALL BRYANT & HAMILL, LLC Granite Investment Partners, LLC

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 17 shared holders

BRAIDWELL LP Frazier Life Sciences Management, L.P.TFG Asset Management GP Ltd

CPRX

CATALYST PHARMACEUTICALS, INC.

AI score

Similar quality profile · 14 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Bridge City Capital, LLC KENNEDY CAPITAL MANAGEMENT LLC

ISRG

INTUITIVE SURGICAL INC

AI score

Similar quality profile · 14 shared holders

Capital World Investors 1832 Asset Management L.P.ORBIMED ADVISORS LLC

TGTX

TG THERAPEUTICS, INC.

AI score

Similar quality profile · 25 shared holders

Soleus Capital Management, L.P.Hood River Capital Management LLC Bridgewater Associates, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KRYS on your watchlist

Track score changes the day Krystal Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KRYS a good stock to buy?

13F Pro's AI-powered analysis of Krystal Biotech, Inc. (KRYS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KRYS are available on the KRYS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KRYS is classified as a large company.

Which hedge funds own KRYS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KRYS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Krystal Biotech, Inc.'s investment landscape.